Jul 10, 2024, 06:48 AM by

Pascal Piedbois, MD, PhD joins One2Treat as Chief Medical Officer to advance patient-centric innovation in clinical trial design and market access. One2Treat reflects patient priorities in a single multi-facet treatment assessment, reducing trial sample size and accelerating patient access to new treatments.

Jul 10, 2024, 06:48 AM by

DoseMe, a leading provider of model-informed precision dosing (MIPD), announced today it has earned certified status by HITRUST for information security. HITRUST Risk-based, 2-year (r2) Certification demonstrates that the organization’s DoseMeRX has met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk. This achievement places DoseMe in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls. DoseMe remains the only model informed precision dosing platform to achieve the r2 Certification.

Jul 10, 2024, 06:48 AM by

SMi Systems announces the appointment of Dr Stefan Hamill as its Vice President of Strategy. Dr Hamill was formerly a senior analyst at investment banks Numis (now Deutsche Numis) and Peel Hunt, both of which he helped transform into #1 ranked franchises in UK Life Sciences.

Jul 10, 2024, 06:48 AM by

The first-of-its-kind collaboration combines personalized genetic insights with evidence-based treatments to provide accessible and effective obesity care for women

Jul 10, 2024, 06:48 AM by

Jul 10, 2024, 05:00 AM by User Not Found

Bio-IT World | Until recently, all the available therapeutic options for treating Alzheimer’s disease were designed to reduce symptoms rather than address causes of the disease. But with two beta-amyloid antibodies now approved by the U.S. Food and Drug Administration, and tau-targeting agents in clinical trials, hopes are rising that Alzheimer’s progression can be delayed if not stopped.

Jul 9, 2024, 16:22 PM by User Not Found

Bio-IT World | Illumina has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology. Fluent Biosciences is now a wholly owned subsidiary of Illumina and was acquired with cash on hand.

Jul 9, 2024, 05:00 AM by User Not Found

Bio-IT World | When Regeneron began exploring how to digitize scientific information in lab environments, IT engineers didn’t begin by brainstorming their own ideas. They began by shadowing scientists.

Jul 8, 2024, 08:37 AM by

Jul 8, 2024, 08:37 AM by

Jul 3, 2024, 07:13 AM by

Jul 3, 2024, 07:13 AM by

Optibrium announced the publication of a peer-reviewed study in Journal of Computer-Aided Molecular Design, ‘From UK-2A to florylpicoxamid: Active learning to identify a mimic of a macrocyclic natural product’. The paper demonstrates the successful application of the QuanSA (Quantitative Surface-field Analysis) method, part of Optibrium’s BioPharmics platform for 3D molecular design, to accelerate the lead optimisation of a complex macrocyclic natural product during agrochemical development. By significantly reducing the number of synthetic steps required during optimisation, the study supports the commercial viability of complex macrocyclic compounds.

Jul 3, 2024, 07:12 AM by

Indica Labs today announces the expansion of their reseller network in the Asia Pacific (APAC) region.

Jul 2, 2024, 08:45 AM by

Jul 2, 2024, 08:45 AM by

Watson-Marlow’s 323Du/D and 323Du/RL peristaltic pumps are available as an accessory with the CellMaker single-use bioreactor systems

Jul 2, 2024, 08:45 AM by

BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon

Jul 1, 2024, 10:05 AM by User Not Found

Bio-IT World | The biotech sector has weathered some recent headwinds in the funding market but is marked by a general air of confidence as we come to close the first quarter of 2024. This confidence was noted in our recent survey of over 130 decision makers in biotech companies, where we found that despite challenging conditions, 87% of respondents reported at least some confidence and 38% were very confident in the overall success of their product.

Jul 1, 2024, 08:55 AM by

Genuus Asia, a prominent name in digital marketing innovation, proudly announces the launch of its comprehensive B2B digital marketing services.

Jul 1, 2024, 08:55 AM by

DoseMe, a leading provider of model-informed precision dosing (MIPD) software, announced today the general availability of its enhanced web-based platform. These technical improvements streamline the workflow and offer the same user experience as fully integrated DoseMeRx customers. This change offers caregivers improved efficiencies.

Jun 28, 2024, 07:44 AM by